Your Location

London

Shanghai

lagos

New York

Sydney

  • Country: Loading...
  • City: Loading...

Science, Biotech & Pharmaceuticals Investments

Core Equivalence - Header  
Science, Biotech & Pharmaceuticals Investments
Continent / Region : /
Country : Guinea-Bissau
Location :
Industry : Science, Biotech & Pharmaceuticals
Finance Type : Any Finance Type
Transaction Type : Any transaction type
Business Type : Mergers and Acquisitions
Sell Side or Buy Side :
Our investors are interested Science, Biotech & Pharmaceuticals Investments, Business developments and Implementations, and applicable Science, Biotech & Pharmaceuticals human resources and service experts in the Guinea-Bissau. Will like to support investors and clients in these initiatives and ventures. Requirements and expertise required are not limited to the following: * promoting the investments and development of Science, Biotech & Pharmaceuticals * maintenance or improvement of health solution via Science, Biotech & Pharmaceuticals * Science, Biotech & Pharmaceuticals development policies in places, communities and countries * Analysis and development of Science, Biotech & Pharmaceuticals systems * Science, Biotech & Pharmaceuticals Equipments and facilities * Science, Biotech & Pharmaceuticals Planning * Well maintained Science, Biotech & Pharmaceuticals facilities and logistics to deliver quality medicines and technologies. * help participating experts and companies, in the legal process and framework, to design appropriate and effective marketing strategies to overcome local and international barriers. * Outsourcing * Start up * Balance growth and environmental concerns. PLEASE, submit interest that will assist in matching buyers and sellers. Note: This proposition does not bind the buyer or seller to any offer, financial or otherwise.

Cost or price of Mergers and Acquisitions
£ 246000
Net Income
£ 0.00
Reference :
Potential Revenue : Over 10% to 15% of current revenue
Potential Expenditure Reduction : Over 15% of current expenditure
Potential Net Profit : Beyond 15%
Start Date :
End Date :
Security Clearance :
Any Current Debt :
Preferred / Required Transaction Timeframe : 90 days
Post Duration :
Advisory Service : Yes
Preferred / Required Transaction Timeframe : 90 days
Reason for sale :
Signed Letter of Intent :
Signed NDA Applicable :
Signed Financial Status Report Applicable :
Business Language :
Net Profit : Aleast 10% to 15% of revenue

Reference Number : CE-208099-UK-ALL-SBP-208099

CoreEquivalence Important Disclosures